San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients ...

Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...

and we are particularly excited to announce the updated SLS009 Phase 2a data at ASH in December and to provide topline data from cohorts four and five in patients with relapsed/refractory (R/R) acute ...

Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami ...

Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...

Dr. Catalina Amador is a co-author. Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Dr. Justin M. Watts is a ...

Copies of the abstracts are now available online on the ASH website ... in patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML ...

"The data being presented this year at ASH demonstrate Syndax's commitment ... patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid ... at the 66th American Society of Hematology ...